fda drug shortage list semaglutide status january 2025 Injections and the FDA Issues Order on Resolution
Description
Expert takeaway Karen Berger, Pharm
Retatrutide at 12mg weekly produced 24.2% body weight loss in Phase 2 trials, which is the highest recorded for any single compound in obesity research
This record proves valuable when discussing progress with healthcare providers
Ozempic has indications for only TYPE 2DM and will not be approved for weight loss
Lab work, consult re-runs, and certain tier upgrades may incur additional cost depending on provider confirm on the provider page before signup
The body composition substudy enrolled 189 participants from the main trial, providing more robust DEXA data than the smaller Mazdutide subsample
